{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T01:28:29.974525+00:00","company":{"ticker":"NEPH","cik":1196298,"company_name":"NEPHROS INC"},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"d8a024424a13be31561b0fc5460f7b0b6130e25c","cik":1196298,"ticker":"NEPH","company_name":"NEPHROS INC","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$140,000","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$5.2 million"},"claim":"NEPHROS INC reported first quarter ended March 31, 2026 results: revenue $5.2 million, net income $140,000.","evidence_excerpt":"Net revenue was $5.2 million, compared to $4.9 million in the first quarter of 2025, up 7% ● Net income was $140,000, compared to a net income of $558,000 in the first quarter of 2025","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001493152-26-021734","anchor_url":"https://secwatch.observer/filing/0001493152-26-021734#claim-d8a024424a13be31561b0fc5460f7b0b6130e25c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1196298/000149315226021734/0001493152-26-021734-index.htm"},{"fact_type":"executive_change","fact_key":"115f0060f1","cik":1196298,"ticker":"NEPH","company_name":"NEPHROS INC","filed_at":"2025-04-28T23:59:59+00:00","payload":{"action":"will not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":"2025-06-16","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Alisa Lask departed as Director at NEPHROS INC.","evidence_excerpt":"On April 23, 2025, Alisa Lask notified the Board of Directors (the “Board”) of Nephros, Inc. (the “Company”) that she will not stand for re-election to the Board at the Company’s annual meeting of stockholders scheduled to be held on June 16, 2025 (the “2025 Annual Meeting”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-006427","anchor_url":"https://secwatch.observer/filing/0001641172-25-006427#claim-115f0060f1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1196298/000164117225006427/0001641172-25-006427-index.htm"},{"fact_type":"earnings_release","fact_key":"c5673a49825238eeaaa3633d3fd37e72bf335ac5","cik":1196298,"ticker":"NEPH","company_name":"NEPHROS INC","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss of $0.2 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$3.5 million"},"claim":"NEPHROS INC reported first quarter ended March 31, 2024 results: revenue $3.5 million, net income Net loss of $0.2 million.","evidence_excerpt":"Nephros Announces Financial Results for Quarter Ended March 31, 2024 First-Quarter Net Revenue of $3.5 Million","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001493152-24-018435","anchor_url":"https://secwatch.observer/filing/0001493152-24-018435#claim-c5673a49825238eeaaa3633d3fd37e72bf335ac5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1196298/000149315224018435/0001493152-24-018435-index.htm"},{"fact_type":"earnings_release","fact_key":"a77d5f34df99958519843a9acb6ebaa3ae52f242","cik":1196298,"ticker":"NEPH","company_name":"NEPHROS INC","filed_at":"2024-03-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss from continuing operations was ($1.6 million)","period_text":"the fourth quarter and fiscal year ended December 31, 2023","report_date":"2024-03-07","result_type":"reported_results","revenue_text":"Net revenue from continuing operations was $14.2 million"},"claim":"NEPHROS INC reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue Net revenue from continuing operations was $14.2 million, net income Net loss from continuing operations was ($1.6 million).","evidence_excerpt":"Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-009216","anchor_url":"https://secwatch.observer/filing/0001493152-24-009216#claim-a77d5f34df99958519843a9acb6ebaa3ae52f242","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1196298/000149315224009216/0001493152-24-009216-index.htm"}]}